Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
'Officer attaining rank of Field Marshal, Marshal of the Air Force, Admiral of the Fleet to retain uniform for life'
- 14 hours ago
Google to manufacture 600,000 Chromebooks annually in Pakistan: Shaza
- 18 hours ago
‘Eyes-off driving’ is coming, and we’re so not ready
- 6 hours ago
US Boycotts G20 in South Africa Over ‘White Genocide’ Claim
- an hour ago
Nation marks Iqbal Day with pledge to get inspiration from his principles, ideals
- an hour ago
The tragedy of Laika, the first animal to orbit the earth
- 4 hours ago
PM Shehbaz vows to safeguard Pakistan’s territorial integrity
- 15 hours ago
Pakistan, Afghanistan peace talks collapse, ceasefire continues, Taliban says
- 18 hours ago
Saim Ayub steers Pakistan to ODI series win over South Africa
- 18 hours ago
Sami Yusuf, Atif Aslam’s Sufi performance captivates fans
- 14 hours ago
iOS 26.1 lets you tweak Liquid Glass, and it’s out now
- 6 hours ago
Gold prices plummet in Pakistan, global markets
- 18 hours ago
